A current overview of the pharmacological composition of "La Chimique" consumed in Mayotte: Preliminary results of the CHASSE-MAREE protocol.
LC-HRMS
Mayotte
synthetic cannabinoids
“La Chimique”
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
05 Oct 2023
05 Oct 2023
Historique:
revised:
20
09
2023
received:
24
07
2023
accepted:
22
09
2023
medline:
6
10
2023
pubmed:
6
10
2023
entrez:
6
10
2023
Statut:
aheadofprint
Résumé
Mayotte Island, a French department located in the Mozambique Channel, has for several years been faced with the consumption of "La Chimique" (LC), reputed (but extremely poorly documented) to be a mixture of tobacco and synthetic cannabinoid receptor agonists (SCRAs). One of the objectives of the CHASSE-MAREE protocol is to assess the composition and heterogeneity of LC products through successive LC sample collection campaigns among users. Currently underway, we present here the first analytical results (samples collected in 2022). Between September and December 2022, 80 samples were collected throughout the island over three periods: 70 in the usual form of LC (small folded papers containing a plant-like sample, mostly tobacco), 6 powders, and 4 cigarettes. Analysis was performed using liquid chromatography with high-resolution mass spectrometry. The detected substances (number of detections) included SCRAs (MDMB-4en-PINACA [35], ADB-FUBIATA [25], MDMB-INACA [16], ADB-BUTINACA [15], AFUBIATA [11], 4F-MDMD-BICA [7], CH-PIATA [14], 5C-APINACA [3], BZO-HEXOXIZID [2], and 4F-ABINACA [1]), nicotine (68), tetrahydrocannabinol (THC), cannabinol (CBN), and cannabidiol (CBD) (2), medications (amantadine [11], cyamemazine [6], and acetaminophen [3]), and a designer benzodiazepine (bromazolam [4]). The SCRAs currently in use are varied, and the market for "cooks" (those who prepare LC) is dispersed according to where and when samples are collected. These preliminary results will be supplemented by analysis of samples collected in the first half of 2023 and by an improved description of the current panorama of consumption of LC in Mayotte (mapping, effects felt and dependence, etc.).
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Regional Health Agency of Mayotte
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Roussel O, Carlin MG, Bouvot X, Tensorer L. The emergence of synthetic cannabinoids in Mayotte. Toxicol Anal Clin. 2015;27(1):18-22. doi:10.1016/j.toxac.2014.12.002
Daveluy A, Haramburu F. Psychoactive substances use in Réunion Island and Mayotte, French departments in Indian Ocean. Therapie. 2018;73(5):419-427. doi:10.1016/j.therap.2018.01.007
Goncalves R, Peyré A, Castaing N, et al. Minors and young adult's hospitalizations after “chimique” consumption in Mayotte Island: which substances are involved? Therapie. 2023;78(3):235-240. doi:10.1016/j.therap.2022.07.007
French Monitoring Center for Drugs and Drug Addiction (OFDT): the supply, use and impact of “chemical” consumption in Mayotte: a qualitative study, Cadet-Taïro A and Gangilhon M, May 2018;80p. Accessed June 25, 2023. https://www.ofdt.fr/BDD/publications/docs/epfxacy5.pdf
Richeval C, Humbert L, Nefau T, Martinez M, Allorge D, Gaulier JM. The comeback of ecstasy: new designs and increased MDMA content. Toxicol Anal Clin. 2017;29(1):144-145. doi:10.1016/j.toxac.2016.09.003
Gaulier JM, Richeval C, Phanithavong M, Brault S, Allorge D, Dumestre-Toulet V. A case report of carfentanil-related fatality in France. Toxicol Anal Clin. 2019;31(4):323-331. doi:10.1016/j.toxac.2019.01.002
Mardal M, Andreasen MF, Mollerup CB, et al. HighResNPS.com: an online crowd-sourced HR-MS database for suspect and non-targeted screening of new psychoactive substances. J Anal Toxicol. 2019;43(7):520-527. Erratum in: J Anal Toxicol 2019;43(6):e7-e8. PMID: 31095696. doi:10.1093/jat/bkz030
Osipenko S, Nikolaev E, Kostyukevich Y. Retention time prediction with message-passing neural networks. Separations. 2022;9(10):291. doi:10.3390/separations9100291
Wang F, Liigand J, Tian S, Arndt D, Greiner R, Wishart DS. CFM-ID 4.0: more accurate ESI-MS/MS spectral prediction and compound identification. Anal Chem. 2021;93(34):11692-11700. doi:10.1021/acs.analchem.1c01465
Tsugawa H, Cajka T, Kind T, et al. MS-DIAL: data-independent MS/MS deconvolution for comprehensive metabolome analysis. Nat Methods. 2015;12(6):523-526. doi:10.1038/nmeth.3393
European Monitoring Centre for Drugs and Drug Addiction. MDMB-4en-PINACA: EMCDDA Risk Assessments. Publications Office of the European Union; 2022. doi:10.2810/007489. Accessed July 5, 2023. https://www.emcdda.europa.eu/system/files/media/publications/documents/13680/emcdda-RAR-MDMB-4en-PINACA_NEW.pdf
Norman C, Halter S, Haschimi B, et al. A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: comparing prison and general populations. Drug Test Anal. 2021;13(4):841-852. doi:10.1002/dta.3002
International Collaborative Exercises-Drug Analysis. 2021. United Nations Office on Drugs and Crime. Accessed July 5, 2023. https://www.unodc.org/documents/scientific/ICE_Drug_Analysis_Report_2021.pdf
Andrews R, Jorge R, Christie R, Gallegos A. From JWH-018 to OXIZIDS: structural evolution of synthetic cannabinoids in the European Union from 2008 to present day. Drug Test Anal. 2023;15(4):378-387. doi:10.1002/dta.3422
Deventer MH, Van Uytfanghe K, Vinckier IMJ, Reniero F, Guillou C, Stove CP. A new cannabinoid receptor 1 selective agonist evading the 2021 “China ban”: ADB-FUBIATA. Drug Test Anal. 2022;14(9):1639-1644. doi:10.1002/dta.3285
Analytical report-MDMB-INACA. National Forensic Laboratory, Liubliana, Slovenia. Accessed July 5, 2023. https://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/MDMB-INACA-ID-2074-19_report.pdf
King A, Hill SL, Pucci M, et al. Clinical features associated with ADB-BUTINACA exposure in patients attending emergency departments in England. Clin Toxicol (Phila). 2022;60(10):1094-1098. doi:10.1080/15563650.2022.2101469
Drug Analysis Service and Cannabis Laboratories-Government of Canada, Analyzed Drug Report January to March 2023. Accessed July 5, 2023. https://health-infobase.canada.ca/drug-analysis-service/analyzed-drug-report.html
Körmöczi T, Sija É, Institóris L, Kereszty ÉM, Ilisz I, Berkecz R. Analytical methodologies for the characterization and analysis of the parent compound and phase I metabolites of 4F-MDMB-BICA in human microsome, urine, and blood samples. J Anal Toxicol. 2021;46(2):135-145. doi:10.1093/jat/bkab004
NPS Discovery-Center for Forensic Science Research and Education (CFSRE). CH-PIATA CFSRE Chemistry Report. 2022. Accessed July 5, 2023. https://www.cfsre.org/images/monographs/CH-PIATA-042922-CFSRE-Chemistry-Reportpdf
de Araujo KRG, Fabris AL, Neves Júnior LF, et al. The mystery behind the apprehensions of the selective cannabinoid receptor type-2 agonist BZO-HEXOXIZID (MDA-19) as a drug of abuse. Forensic Toxicol. 2023;41(1):142-150. doi:10.1007/s11419-022-00646-6
NMS LABS-Center for Forensic Science Research and Education (CFSRE). 4F-ABINACA. Accessed July 5, 2023. https://www.cfsre.org/images/monographs/4F-ABINACA_012721_NMSLabs_Report.pdf
Analytical report-4F-ABUTINACA. National Forensic Laboratory, Liubliana, Slovenia. Accessed July 5, 2023. https://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/4F-ABUTINACA-ID-2240-21_report.pdf
Oberenko AV, Kachin SV, Sagalakov SA. Profiling of impurities in samples of synthetic cannabinoids seized from illegal circulation in the Siberia region of the Russian Federation. J Sib Fed Univ Chem. 2018;11(3):310-322. doi:10.17516/1997-2836-0077
Bromazolam detected in the Northwest Territories-Health and Social Services, Canada. Accessed July 5, 2023. https://www.hss.gov.nt.ca/fr/newsroom/d%C3%A9tection-de-bromazolam-aux-territores-du-nord-ouest